PT  - JOURNAL ARTICLE
AU  - Samuel Alizon
TI  - Treating symptomatic infections and the co-evolution of virulence and drug resistance
AID  - 10.1101/2020.02.29.970905
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.02.29.970905
4099  - http://biorxiv.org/content/early/2020/10/22/2020.02.29.970905.short
4100  - http://biorxiv.org/content/early/2020/10/22/2020.02.29.970905.full
AB  - Antimicrobial therapeutic treatments are by definition applied after the onset of symptoms, which tend to correlate with infection severity. Using mathematical epidemiology models, I explore how this link affects the coevolutionary dynamics between the virulence of an infection, measured via host mortality rate, and its susceptibility to chemotherapy. I show that unless resistance pre-exists in the population, drug-resistant infections are initially more virulent than drug-sensitive ones. As the epidemic unfolds, virulence is more counter-selected in drug-sensitive than in drug-resistant infections. This difference decreases over time and, eventually, the exact shape of genetic trade-offs govern long-term evolutionary dynamics. Using adaptive dynamics, I show that two types of evolutionary stable strategies (ESS) may be reached in the context of this simple model and that, depending on the parameter values, an ESS may only be locally stable. In general, the more the treatment rate increases with virulence, the lower the ESS value. Overall, both on the short-term and long-term, having treatment rate depend on infection virulence tend to favour less virulent strains in drug-sensitive infections. These results highlight the importance of the feedbacks between epidemiology, public health policies and parasite evolution, and have implications for the monitoring of virulence evolution.Competing Interest StatementThe authors have declared no competing interest.